The problem with Progesterone trial was reliance on subjective target points. 50% of progesterone patients had positive function outcomes. Only problem is so did placebo patients.
All eyes on biomarkers like non convulsive seizures in our trial.
A possibility worth worth contemplating, page-31
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |